Colon cancer treatment is personalized based on stage, overall health and tumor characteristics. Early detection and accurate ...

INDIANAPOLIS (WISH) – This week, the United States Food and Drug Administration approved Guardant’s Shield blood test to screen for colon cancer in average-risk Americans 45 to 75 years old.

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

For years, the gold standard in screening for colon cancer has been a colonoscopy. But a colonoscopy is a medical procedure that involves length prep work, along with being put under, making it ...

According to Cologuard, made by Wisconsin-based Exact Sciences, there are three primary reasons why you may receive a testing ...

MINNEAPOLIS — A possible medical game-changer as the FDA approves a new blood test for colon cancer. On Monday, the Food and Drug Administration approved Guardant Health's blood test called 'Shield.' ...

The Food and Drug Administration (FDA) has recently approved a blood test that can assist in the primary detection of colorectal cancer. This test could assist with prompt detection and intervention ...

The Food and Drug Administration (FDA) has approved a new blood test to detect colon cancer. The blood test, manufactured by Guardant Health’s Shield, does not replace colonoscopies. Colorectal cancer ...

Guardant Health, Inc., a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening is now covered for active-duty service members and their families ...

Colonoscopy is the gold standard for detecting colon cancer, but every year about 50 million people in the U.S. who qualify for a colonoscopy don't get it done, according to the American Cancer ...